Society for Endocrinology - Media Release

For immediate release

Society for Endocrinology releases updated position statement on the use of dopamine agonists in endocrine disorders

The Society for Endocrinology has issued an updated position statement concerning the use of dopamine agonists in the treatment of patients with endocrine disorders. The full statement can be viewed at:

http://www.endocrinology.org/policy/

Low doses of dopamine agonists are routinely used in the treatment of pituitary disorders such as hyperprolactinaemia or acromegaly. Over the last decade, evidence has emerged that the use of high doses in the management of Parkinson’s disease is associated with cardiac valve fibrosis.

The Society for Endocrinology has released this updated position statement in light of concerns over the association of chronic use of low doses of dopamine agonists (cabergoline and bromocriptine) for the treatment of endocrine patients with a risk of cardiac valve fibrosis(1).

----------Ends----------

Notes for editors:

The full statement can be viewed at: http://www.endocrinology.org/policy/

The Society for Endocrinology is the major British society representing scientists, clinicians and nurses who work with hormones. We aim to advance education and research in endocrinology for the public benefit and to promote endocrinology and hormone awareness to the wider community. For general information, please visit our website: www.endocrinology.org

Please mention the Society for Endocrinology in any story

For more information: please contact the Society for Endocrinology press office

Rebecca Ramsden
Public & Media Relations Assistant
01454 642 252
rebecca.ramsden@endocrinology.org

Jennie Evans
Public & Media Relations Officer
01454 642 230
jennie.evans@endocrinology.org

References:

(1) MHRA Drug Safety Update
http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON028267